RECKITT BENCKIS/S (OTCMKTS:RBGLY) Upgraded to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of RECKITT BENCKIS/S (OTCMKTS:RBGLY) from a sell rating to a hold rating in a research report report published on Thursday, September 20th.

According to Zacks, “Reckitt Benckiser Group Plc engages in manufacturing and distributing household, toiletry, pharmaceutical and food products. The company offers antiseptic liquids, depilatory products, medicated sore throat products, condoms, cold/flu products, acne treatment products, analgesics and upper gastro-intestinal products, foot care and comfort footwear products, denture care and dry skin care products, fabric care products, surface care products and polishes/waxes. Reckitt Benckiser Group is based in Slough, the United Kingdom. “

Shares of OTCMKTS RBGLY traded up $0.12 during mid-day trading on Thursday, hitting $17.13. 384,707 shares of the stock traded hands, compared to its average volume of 714,995. The company has a quick ratio of 0.50, a current ratio of 0.68 and a debt-to-equity ratio of 0.75. RECKITT BENCKIS/S has a 52 week low of $15.14 and a 52 week high of $21.79. The firm has a market capitalization of $64.78 billion, a PE ratio of 24.46, a P/E/G ratio of 4.59 and a beta of 0.97.


Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

See Also: How analysts view the yield curve

Get a free copy of the Zacks research report on RECKITT BENCKIS/S (RBGLY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with's FREE daily email newsletter.

Leave a Reply